Kian-Huat Lim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3720030/publications.pdf

Version: 2024-02-01

67 papers	5,668 citations	201674 27 h-index	118850 62 g-index
68 all docs	68 docs citations	68 times ranked	9749 citing authors

#	Article	IF	Citations
1	Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Final analysis of a phase II trial.. Journal of Clinical Oncology, 2022, 40, 284-284.	1.6	0
2	A pilot study of liposomal irinotecan plus 5-FU/ LV combined with paricalcitol in patients with advanced pancreatic cancer which progressed on gemcitabine-based therapy.. Journal of Clinical Oncology, 2022, 40, 566-566.	1.6	2
3	Evolving Paradigms in the Systemic Treatment of Advanced Gallbladder Cancer: Updates in Year 2022. Cancers, 2022, 14, 1249.	3.7	9
4	IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2022, 162, 2047-2062.	1.3	18
5	CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusionsâ€"A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).. Journal of Clinical Oncology, 2021, 39, TPS449-TPS449.	1.6	2
6	Phase II/III study of SM-88 in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, 437-437.	1.6	4
7	CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. ACS Nano, 2021, 15, 1186-1198.	14.6	32
8	Combined Systemic and Hepatic Artery Infusion Pump Chemo-Therapy as a Liver-Directed Therapy for Colorectal Liver Metastasis-Review of Literature and Case Discussion. Cancers, 2021, 13, 1283.	3.7	7
9	A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma. Oncologist, 2021, 26, 722-726.	3.7	3
10	Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects. World Journal of Gastroenterology, 2021, 27, 2105-2121.	3.3	17
11	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications, 2021, 12, 5086.	12.8	58
12	Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies. European Journal of Cancer, 2021, 154, 102-110.	2.8	6
13	Nonoperative Rectal Cancer Management With Short-Course Radiation Followed by Chemotherapy: A Nonrandomized Control Trial. Clinical Colorectal Cancer, 2021, 20, e185-e193.	2.3	20
14	Phospho-Ser784-VCP Drives Resistance of Pancreatic Ductal Adenocarcinoma to Genotoxic Chemotherapies and Predicts the Chemo-Sensitizing Effect of VCP Inhibitor. Cancers, 2021, 13, 5076.	3.7	2
15	Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities. Cancers, 2021, 13, 5481.	3.7	11
16	The MK2/Hsp27 axis is a major survival mechanism for pancreatic ductal adenocarcinoma under genotoxic stress. Science Translational Medicine, 2021, 13, eabb5445.	12.4	5
17	Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. Gut, 2020, 69, 122-132.	12.1	89
18	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma. JAMA Oncology, 2020, 6, 60.	7.1	112

#	Article	IF	Citations
19	Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal Transduction and Targeted Therapy, 2020, 5, 249.	17.1	88
20	Deciphering the Role of Innate Immune NF-Ä¸B Pathway in Pancreatic Cancer. Cancers, 2020, 12, 2675.	3.7	12
21	FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers. JAMA Oncology, 2020, 6, 1231.	7.1	12
22	The clonal evolution of metastatic colorectal cancer. Science Advances, 2020, 6, eaay9691.	10.3	41
23	Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2020, 11, 61-67.	1.4	5
24	TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations. Journal of Clinical Investigation, 2020, 130, 4771-4790.	8.2	20
25	Final results of a phase II trial of first-line FOLFIRINOX for advanced gastroesophageal cancers.. Journal of Clinical Oncology, 2020, 38, 4532-4532.	1.6	0
26	Folate Receptor Î±-Targeted 89Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer. Molecular Pharmaceutics, 2019, 16, 3996-4006.	4.6	12
27	Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clinical Cancer Research, 2019, 25, 6107-6118.	7.0	54
28	IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer. JCI Insight, 2019, 4, .	5.0	26
29	Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, TPS4150-TPS4150.	1.6	1
30	Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression. Hepatology Communications, 2018, 2, 148-151.	4.3	16
31	Tumorâ€“Stroma IL1Î²-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer. Cancer Research, 2018, 78, 1700-1712.	0.9	134
32	Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Molecular Cancer Therapeutics, 2018, 17, 2144-2155.	4.1	32
33	Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. Hpb, 2017, 19, 133-139.	0.3	54
34	Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 2199-2204.	2.0	7
35	Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2017, 23, 1748-1759.	7.0	56
36	Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature. Journal of Gastrointestinal Oncology, 2017, 8, 379-386.	1.4	19

#	Article	IF	Citations
37	Current biologics for treatment of biliary tract cancers. Journal of Gastrointestinal Oncology, 2017, 8, 430-440.	1.4	33
38	Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer. Journal of Gastrointestinal Oncology, 2017, 8, 985-989.	1.4	14
39	Immunotherapy in gastrointestinal cancers. Journal of Gastrointestinal Oncology, 2017, 8, 474-484.	1.4	36
40	A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2017, 35, 410-410.	1.6	6
41	Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer.. Journal of Clinical Oncology, 2017, 35, TPS505-TPS505.	1.6	2
42	A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. Oncotarget, 2017, 8, 24250-24261.	1.8	8
43	Analysis of the effect of adjuvant therapy on overall survival for resected gallbladder adenocarcinoma using the National Cancer Database.. Journal of Clinical Oncology, 2017, 35, 360-360.	1.6	0
44	Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.. Journal of Clinical Oncology, 2017, 35, 2553-2553.	1.6	0
45	Entering the molecular era of gastrointestinal oncology: current updates and challenges. Journal of Gastrointestinal Oncology, 2017, 8, 377-378.	1.4	0
46	Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncology, The, 2016, 17, 651-662.	10.7	557
47	Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Therapeutic Advances in Medical Oncology, 2015, 7, 68-84.	3.2	123
48	FOLFIRINOX as first-line therapy in patients with metastatic gastroesophageal cancers (GEC).. Journal of Clinical Oncology, 2015, 33, 177-177.	1.6	2
49	Phase IB study of FOLFIRINOX plus PF-04136309 in patients with borderline resectable and locally advanced pancreatic adenocarcinoma (PC).. Journal of Clinical Oncology, 2015, 33, 338-338.	1.6	11
50	Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 763-763.	1.6	1
51	Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.. Journal of Clinical Oncology, 2014, 32, TPS2644-TPS2644.	1.6	0
52	Toll-Like Receptor Signaling. Cold Spring Harbor Perspectives in Biology, 2013, 5, a011247-a011247.	5.5	306
53	Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?. Oncologist, 2012, 17, 192-200.	3.7	83
54	Pathogenetic importance and therapeutic implications of NFâ€ºB in lymphoid malignancies. Immunological Reviews, 2012, 246, 359-378.	6.0	129

#	Article	IF	Citations
55	IRAK4 Kinase As A Novel Therapeutic Target in the ABC Subtype of Diffuse Large B Cell Lymphoma. Blood, 2012, 120, 62-62.	1.4	12
56	RALA and RALBP1 regulate mitochondrial fission atÂmitosis. Nature Cell Biology, 2011, 13, 1108-1115.	10.3	327
57	Oncogenically active MYD88 mutations in human lymphoma. Nature, 2011, 470, 115-119.	27.8	1,292
58	Sec5 and Exo84 Foster Oncogenic Ras-Mediated Tumorigenesis. Molecular Cancer Research, 2010, 8, 223-231.	3.4	34
59	Aurora-A Phosphorylates, Activates, and Relocalizes the Small GTPase RalA. Molecular and Cellular Biology, 2010, 30, 508-523.	2.3	100
60	Tumour maintenance is mediated by eNOS. Nature, 2008, 452, 646-649.	27.8	289
61	The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis. Cancer Research, 2008, 68, 7561-7569.	0.9	234
62	Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes and Development, 2007, 21, 1714-1719.	5.9	346
63	Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells. Current Biology, 2006, 16, 2385-2394.	3.9	212
64	Use of Retrovirus Expression of Interfering RNA to Determine the Contribution of Activated Kâ€Ras and Ras Effector Expression to Human Tumor Cell Growth. Methods in Enzymology, 2006, 407, 556-574.	1.0	21
65	Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell, 2005, 7, 533-545.	16.8	330
66	Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell, 2005, 8, 381-392.	16.8	168
67	Leveling the Playing Field. Molecular Cell, 2004, 15, 491-492.	9.7	5